Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07348055
PHASE1/PHASE2
A Study of GR1803 in Systemic Lupus Erythematosus
Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
View on ClinicalTrials.gov
Summary
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
Official title: A Phase Ib/IIa Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GR1803 Injection in Subjects With Systemic Lupus Erythematosus
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
44
Start Date
2026-02-02
Completion Date
2027-12-01
Last Updated
2026-03-10
Healthy Volunteers
No
Interventions
BIOLOGICAL
GR1803 injection
step-up dosing, Dose and frequency according to the protocol
Locations (1)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China